Vivoquant post processing software

Manufactured by Invicro

Sourced in United States

VivoQuant is a post-processing software designed for medical image analysis. It provides tools for visualizing and quantifying data from various imaging modalities, including PET, SPECT, CT, and MRI.

Automatically generated - may contain errors

Lab products found in correlation

Nanospect ct, by Mediso (4 mentions) Nanospect cttm, by Mediso (3 mentions) Nucline software, by Bioscan (2 mentions) Nanospect ctplus camera, by Bioscan (1 mentions) 99mo 99mtc generator, by Mallinckrodt (1 mentions)

12 protocols using vivoquant post processing software

Targeted Molecular Imaging of Tumor-Associated Fibroblasts

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were subcutaneously inoculated into the right flank with 9Â10 6 of MC38-FAP cells. When tumors reached the size of about 500 mm 3 , mice were injected with approximately 6 MBq of indium-111-conjugated DARPin molecules, corresponding to 100 kBq per mg of DARPin molecules, into the tail vein.
Single-photon emission computed tomography (SPECT)/X-ray computed tomography (CT) images were performed with the NanoSPECT/CTPlus camera (version 1.2, Bioscan). Acquisitions of SPECT and CT were performed with the software Nucline (version 1.02). The CT was also reconstructed with the software Nucline, whereas for SPECT the software HISPECT was used (version 1.4.3049, Scivis GmbH). Fusions of SPECT and CT data were analyzed with the VivoQuant postprocessing software (Version 3.5, Invicro). Whole-body activity was measured in a gamma counter tube prior to imaging acquisition. SPECT/CT in vivo images were taken from anesthetized mice at time points 4, 24, 48, 72 and 96 hours after injection of 111 In-DARPin constructs. The 3D segmentation tool of the VivoQuant postprocessing software was used for quantification of the measured radioactivity in the tumors.

Rigamonti N., Veitonmäki N., Domke C., Barsin S., Jetzer S., Abdelmotaleb O., Bessey R., Lekishvili T., Malvezzi F., Gachechiladze M., Behe M., Levitsky V, & Trail P.A. (2022). A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression. Cancer immunology research, 10(5).

+ Open protocol

+ Expand

Preclinical PET Imaging of 152Tb-DOTANOC

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET scans were performed with a bench-top preclinical PET/CT scanner (G8, Sofie Biosciences, California, USA and Perkin Elmer, Massachusetts, USA). The energy window ranged from 150 to 650 keV and the spatial resolution of reconstructed images was 1.4 mm full-width-at-half-maximum in the center of the field of view [16 (link)]. The images were acquired as static whole-body scans using G8 acquisition software (version 1.2.9.3) and reconstructed with maximum-likelihood expectation maximization (MLEM). The data were corrected for random coincidences, decay and dead time. Images were prepared using the VivoQuant post-processing software (version 2.1, inviCRO Imaging Services and Software, Boston, USA). Accumulation of ¹⁵²Tb-DOTANOC per volume of tumor and kidney tissue was determined using the “3D ROI” tool of the VivoQuant post-processing software, allowing calculation of the tumor-to-kidney ratios. A Gauss post-reconstruction filter was applied for the presentation of the PET, with the scale adjusted to allow the best visualization of tumors and kidneys in which radioactivity accumulated.

Müller C., Vermeulen C., Johnston K., Köster U., Schmid R., Türler A, & van der Meulen N.P. (2016). Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging. EJNMMI Research, 6, 35.

+ Open protocol

+ Expand

Multimodal Imaging of PSMA-Targeted Radioligands

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET/CT scans were performed using a small-animal bench-top PET/CT scanner (G8, Perkin Elmer, MA, USA; Additional file 1). Mice were injected intravenously with ¹⁵²Tb-PSMA-617 (10 MBq, 1 nmol, 100 μL, diluted in saline) and anesthetized with a mixture of isoflurane and oxygen for in vivo scans (PET/CT and SPECT/CT). Static whole-body PET scans, 10 min in duration, were performed at 2 and 15 h p.i. of the radioligand, followed by a CT scan of 1.5 min. SPECT/CT studies were performed using a small-animal SPECT/CT scanner (NanoSPECT/CTTM, Mediso Medical Imaging Systems, Budapest, Hungary) (Additional file 1). Tumor-bearing mice were intravenously injected with ¹⁷⁷Lu-PSMA-617 (25 MBq, 1 nmol, 100 μL, diluted in saline). Static SPECT/CT scans, 45 min in duration, were performed at 2 h and 15 h p.i. of the radioligand, followed by a CT scan of 7.5 min. Reconstruction of the acquired data was performed using the software of the scanner in question. All images were prepared using VivoQuant post-processing software (version 3.5, inviCRO Imaging Services and Software, Boston, USA). A Gauss post-reconstruction filter (full width at half maximum = 1 mm) was applied to the images and the scale adjusted by cutting 5% of the lower signal intensity to make the tumors and kidneys readily visible.

Müller C., Singh A., Umbricht C.A., Kulkarni H.R., Johnston K., Benešová M., Senftleben S., Müller D., Vermeulen C., Schibli R., Köster U., van der Meulen N.P, & Baum R.P. (2019). Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer. EJNMMI Research, 9, 68.

+ Open protocol

+ Expand

Small-Animal SPECT/CT Imaging of Folate Radioconjugates

Check if the same lab product or an alternative is used in the 5 most similar protocols

The acquisition and analysis of images were performed with a dedicated small-animal SPECT/CT scanner (NanoSPECT/CT™, Mediso Medical Imaging Systems, Budapest, Hungary) as previously reported (Supplementary Material) [18 (link)]. Mice were injected with the folate radioconjugates (25 MBq, 0.5 nmol) and scanned at 4 h and 24 h post injection (p.i.) Images were prepared using VivoQuant post-processing software (version 3.5, inviCRO Imaging Services and Software, Boston, USA). A Gauss post-reconstruction filter (FWHM = 1 mm) was applied, and the scale of activity was set as indicated on the images.

Guzik P., Benešová M., Ratz M., Monné Rodríguez J.M., Deberle L.M., Schibli R, & Müller C. (2020). Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 48(4), 972-983.

+ Open protocol

+ Expand

PET Imaging of Tumor-Bearing Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

A bench-top preclinical PET scanner (G8, Sofie Biosciences, California, U.S.A. and Perkin Elmer, Massachusetts, U.S.A.) was employed for the PET scans of the tumor-bearing mice. The energy window was set to 150–650 keV. Mice were injected intravenously with ⁴⁴Sc- or ⁶⁸Ga-labeled peptides (~10 MBq, ~1 nmol per mouse) in a volume of 100–200 μL. The PET scans were performed 3 h and 5 h after injection of the ⁴⁴Sc-labeled peptides and 3 h after injection of the ⁶⁸Ga-labeled peptides, using G8 acquisition software (version 2.0.0.10). All static PET scans lasted for 20 min. During the acquisition the mice were anesthetized by inhalation of a mixture of isoflurane and oxygen. The images were reconstructed with maximum-likelihood expectation maximization (MLEM). Gauss post-reconstruction filtering was performed using VivoQuant post-processing software (version 2.10, inviCRO Imaging Services and Software, Boston, U.S.A.).

Domnanich K.A., Müller C., Farkas R., Schmid R.M., Ponsard B., Schibli R., Türler A, & van der Meulen N.P. (2016). 44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations. EJNMMI Radiopharmacy and Chemistry, 1, 8.

+ Open protocol

+ Expand

Small-Animal SPECT/CT Imaging of Tumor

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Single-photon emission computed tomography/computed tomography (SPECT/CT) studies were performed approx. two weeks after KB tumor cell inoculation using a small-animal SPECT/CT scanner (NanoSPECT/CT™, Mediso Medical Imaging Systems, Budapest, Hungary) as previously reported (Supplementary Materials Section S13) [28 (link)]. SPECT scans were acquired 1 h, 4 h, 24 h and 48 h after intravenous injection of the radioconjugates (25 MBq, 0.5 nmol/mouse, 100 µL PBS with 0.05% BSA; n = 2) into a lateral tail vein of the mice. The images were reconstructed using HiSPECT software (version 1.4.3049, Scivis GmbH, Göttingen, Germany). The real-time CT reconstruction used a cone-beam-filtered backprojection. The VivoQuant post-processing software (version 3.5, inviCRO Imaging Services and Software, Boston, MA, USA) was used to prepare the images. A Gaussian post-reconstruction filter (full width at half maximum = 1.0 mm) was applied, and the scale of activity was set as indicated on the images.

Busslinger S.D., Becker A.E., Vaccarin C., Deberle L.M., Renz M.L., Groehn V., Schibli R, & Müller C. (2023). Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates. Cancers, 15(17), 4259.

+ Open protocol

+ Expand

Renal Function Assessment in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

The renal function of mice was monitored by the determination of the renal uptake of ^99mTc-DMSA using SPECT, as previously reported [22 (link), 23 (link)]. DMSA (TechneScan®, Mallinckrodt, Petten, The Netherlands) was radiolabeled with ^99mTc (radionuclidic purity >99.9 %), obtained from a ⁹⁹Mo/^99mTc-generator (Mallinckrodt, Petten, The Netherlands) at an activity concentration of 3 GBq in 5 mL. Quality control performed by TLC revealed a radiochemical purity of >95 %. SPECT acquisitions were performed 2 h after the injection of ^99mTc-DMSA (30-40 MBq per mouse) using a NanoSPECT/CT™ (Mediso Medical Imaging Systems, Budapest, Hungary) and Nucline Software (version 1.02, Bioscan Inc., Poway, USA). For this purpose, the energy window of ^99mTc was set to 140.5 ± 14 keV. The acquired data were reconstructed using HiSPECT software (version 1.4.3049, Scivis GmbH, Göttingen, Germany), and the renal uptake of ^99mTc-DMSA was determined, as previously reported, using the VivoQuant post-processing software (version 1.23, inviCRO Imaging Services and Software, Boston, USA) [19 (link)]. The determined activities were decay-corrected and expressed as percentage of injected activity (% IA) per kidney.

Haller S., Pellegrini G., Vermeulen C., van der Meulen N.P., Köster U., Bernhardt P., Schibli R, & Müller C. (2016). Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate. EJNMMI Research, 6, 13.

+ Open protocol

+ Expand

SPECT/CT Imaging of [177Lu]Lu-Ibu-PSMA-02 in Mice

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

SPECT/CT images were obtained using a dedicated small-animal SPECT/CT scanner (NanoSPECT/CT^TM, Mediso Medical Imaging Systems, Budapest, Hungary) as previously reported [21 (link)]. [¹⁷⁷Lu]Lu-Ibu-PSMA-02 (25 MBq, 1 nmol, 100 µL) diluted in saline containing 0.05% BSA was injected in a lateral tail vein of the mouse. SPECT scans of ~45 min duration were performed 4 and 24 h after injection of the radioligand followed by a CT of 7.5 min duration. During the in vivo scans, the mice were anesthetized with a mixture of isoflurane and oxygen. Reconstruction of the acquired data was performed using HiSPECT software (version 1.4.3049, Scivis GmbH, Göttingen, Germany). All images were prepared using VivoQuant post-processing software (version 3.5, inviCRO Imaging Services and Software, Boston, MA, U.S.A.). A Gauss post-reconstruction filter (FWHM = 1.0 mm) was applied to the images and the scale of radioactivity was set as indicated on the images (minimum value = 0.7 Bq/voxel to maximum value = 70 Bq/voxel).

Deberle L.M., Tschan V.J., Borgna F., Sozzi-Guo F., Bernhardt P., Schibli R, & Müller C. (2020). Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile. Molecules, 25(11), 2542.

+ Open protocol

+ Expand

Multimodal Imaging of Radiotracers

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET/CT scans were performed using a small-animal benchtop PET/ CT scanner (G8; Perkin Elmer). The energy window was set to 150-650 keV. Mice were injected intravenously with the 18 F radiotracers (;5 MBq in 100 mL, ;0.2-0.3 nmol). For blocking studies, an excess of folic acid in phosphate buffered saline (100 mg/100 mL) was injected 2-3 min before the injection of the radiotracers.
During the scans, which lasted 10 min, the mice were anesthetized using a mixture of isoflurane and oxygen. Scans were performed at 1, 2, and 3 h after injection of the 18 F radiotracers using G8 acquisition software (version 2.0.0.10). The PET scans were followed by a CT scan of 1.5 min. The images were reconstructed with maximum-likelihood expectation maximization using the software of the scanner. All images were prepared using VivoQuant postprocessing software (version 2.10; inviCRO Imaging Services and Software). A Gauss postreconstruction filter (full width at half maximum, 1 mm) was applied to the images. For presenting the PET/CT images, the scale of the images was adjusted allowing optimal visualization of the tumor tissue und kidneys.

Boss S.D., Müller C., Siwowska K., Schmid R.M., Groehn V., Schibli R, & Ametamey S.M. (2019). Diastereomerically Pure 6R- and 6S-3'-Aza-2'-¹⁸F-Fluoro-5-Methyltetrahydrofolates Show Unprecedentedly High Uptake in Folate Receptor-Positive KB Tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 60(1).

+ Open protocol

+ Expand

Proton Therapy Dose Verification using PET/CT

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET/CT scans were performed using a small-animal bench-top PET/CT scanner (G8, Perkin Elmer, Waltham, MA, USA.) in order to qualitatively estimate the delivered dose distribution by PT [24 (link)]). Due to the compact size of this scanner, it was possible to transport it from CRS to CPT to the OPTIS2 treatment room. PET/CT imaging studies were performed with mice bearing KB tumors or PC-3 PIP tumors, respectively, on each shoulder. The left tumor xenograft of each mouse was irradiated with protons at a dose of 20 Gy. Immediately afterwards, the mouse was placed on the PET animal bed and moved into the scanner (Figure S2). Static whole-body PET scans of 10 min duration were performed followed by a CT of 1.5 min. During the in vivo scans, the mice were anesthetized with a mixture of isoflurane and oxygen. Reconstruction of acquired data was performed using the software of the provider of the G8 scanner. All images were prepared using VivoQuant post-processing software (version 3.0, inviCRO Imaging Services and Software, Boston, MA, USA). A Gauss post-reconstruction filter was applied (FWHM = 1 mm) to the images, which were presented with the scale adjusted by cutting 5% of the lower scale in order to allow visualization of the most important organs and tissues.

Müller C., De Prado Leal M., Dominietto M.D., Umbricht C.A., Safai S., Perrin R.L., Egloff M., Bernhardt P., van der Meulen N.P., Weber D.C., Schibli R, & Lomax A.J. (2019). Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute. Pharmaceutics, 11(9), 450.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!